Literature DB >> 25040880

Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.

Arun Ganti1, Weijian Liu, Suhong Luo, Kristen M Sanfilippo, Ryan Roop, Ryan Lynch, Peter Riedell, Katiuscia O'Brian, Graham A Colditz, Kenneth R Carson.   

Abstract

Entities:  

Keywords:  diffuse large B-cell lymphoma; empiric dose-reduction; non-Hodgkin lymphoma; obesity; treatment-related toxicity

Mesh：

Substances：

Year:  2014        PMID： 25040880      PMCID： PMC4605387          DOI： 10.1111/bjh.13026

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

Review 1.  Interpretation of observational studies.

Authors:  P Jepsen; S P Johnsen; M W Gillman; H T Sørensen
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

2.  Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.

Authors:  Kenneth R Carson; Nancy L Bartlett; Jay R McDonald; Suhong Luo; Angelique Zeringue; Jingxia Liu; Qiang Fu; Su-Hsin Chang; Graham A Colditz
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 3.  Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Authors:  Jennifer J Griggs; Pamela B Mangu; Holly Anderson; Edward P Balaban; James J Dignam; William M Hryniuk; Vicki A Morrison; T May Pini; Carolyn D Runowicz; Gary L Rosner; Michelle Shayne; Alex Sparreboom; Lara E Sucheston; Gary H Lyman
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

4.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

Authors:  P S Romano; L L Roos; J G Jollis
Journal:  J Clin Epidemiol       Date:  1993-10       Impact factor: 6.437

Review 5.  Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.

Authors:  M I Gharib; A K Burnett
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

Review 6.  Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy.

Authors:  Kohei Shitara; Keitaro Matsuo; Isao Oze; Ayako Mizota; Chihiro Kondo; Motoo Nomura; Tomoya Yokota; Daisuke Takahari; Takashi Ura; Kei Muro
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-20       Impact factor: 3.333

7.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Authors:  Gary H Lyman; David C Dale; Jonathan Friedberg; Jeffrey Crawford; Richard I Fisher
Journal:  J Clin Oncol       Date:  2004-09-20       Impact factor: 44.544

8.  Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

Authors:  A Bosly; D Bron; A Van Hoof; R De Bock; Z Berneman; A Ferrant; L Kaufman; M Dauwe; G Verhoef
Journal:  Ann Hematol       Date:  2007-10-20       Impact factor: 3.673

9.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.

Authors:  Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter
Journal:  BMJ       Date:  2009-06-29
  9 in total
  5 in total

1.  Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.

Authors:  Daphne Y Xiao; Suhong Luo; Katiuscia O'Brian; Arun Ganti; Peter Riedell; Kristen M Sanfilippo; Ryan C Lynch; Weijian Liu; Kenneth R Carson
Journal:  Am J Hematol       Date:  2016-07-22       Impact factor: 10.047

2.  The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

Authors:  Vicki A Morrison; Linda McCall; Hyman B Muss; Aminah Jatoi; Harvey J Cohen; Constance T Cirrincione; Jennifer A Ligibel; Jacqueline M Lafky; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2017-12-08       Impact factor: 3.599

3.  Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data.

Authors:  Kristen M Sanfilippo; Tzu-Fei Wang; Brian F Gage; Weijian Liu; Kenneth R Carson
Journal:  Thromb Res       Date:  2015-01-14       Impact factor: 3.944

4.  Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type.

Authors:  Ya-Jun Li; Ping-Yong Yi; Ji-Wei Li; Xian-Ling Liu; Xi-Yu Liu; Fang Zhou; Zhou OuYang; Zhong-Yi Sun; Li-Jun Huang; Jun-Qiao He; Yuan Yao; Zhou Fan; Tian Tang; Wen-Qi Jiang
Journal:  Oncotarget       Date:  2017-01-17

5.  Clinicopathological characteristics and treatment outcome in obese patients with diffuse large B-cell lymphoma.

Authors:  Yu-Ying Wu; Jie-Yu You; Cih-En Huang; Chia-Chen Hsu; Yi-Yang Chen; Hsing-Yi Tsou; Ying-Ju Chen; Chian-Pei Li; Yi-Hua Lai; Chang-Hsien Lu; Ping-Tsung Chen; Chih-Cheng Chen
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.